Introduction {#Sec1}
============

Psychotic disorders are among the world's leading causes of disability^[@CR1]^. Psychosis is often preceded by subtle features, allowing early detection and prevention^[@CR2]^. Preventive approaches in psychosis are grounded on the detection^[@CR3]^, prognostic assessment^[@CR4]^ and treatment^[@CR5]^ of individuals at clinical high-risk for psychosis (CHR-P). CHR-P individuals accumulate risk factors for psychosis^[@CR6]--[@CR8]^ that lead to attenuated positive psychotic symptoms^[@CR9]^, impaired functioning^[@CR10]^ and help-seeking^[@CR11]^. These individuals have approximately 22% risk of developing a first-episode psychosis over the following 3 years^[@CR12]^. Currently, there is no effective intervention that can impact on transition to psychosis, symptom severity or social/functional outcomes in CHR-P^[@CR5]^. Therefore, novel treatments for this population are urgently needed^[@CR5]^.

Impaired autonomic nervous system (ANS) response (i.e., increased sympathetic and/or decreased parasympathetic activation) to environmental challenges has been proposed as a link between the everyday experience of stressors and the emergence of psychotic symptoms---a core pathophysiological mechanism highlighted in stress--diathesis models of psychosis onset^[@CR13],[@CR14]^. Exposure to psychosocial stress, such as life events, childhood trauma or discriminatory experiences in highly vulnerable individuals, is thought to progressively increase the behavioural and biological (ANS and stress endocrine axis (HPA axis)^[@CR15]^) responses to subsequent exposures (a processed one called behavioural sensitisation)^[@CR15]--[@CR17]^. Ultimately, this heightened response to enduring stressors might contribute to sensitise the dopaminergic pathways^[@CR18],[@CR19]^, which have been proposed to underlie psychosis onset^[@CR15]^.

Supporting the contribution of heightened stress response to psychosis, previous studies have reported ANS dysfunction during established psychosis and in CHR-P individuals, beyond what might be explained by medication alone^[@CR20]^. Whether this increased sensitivity to stress is due to a lack of cognitive resources in these patients, such as hampered coping skills or cognitive impairment, or due to the inadequate response of the biologic systems involved in the stress response, is to be fully elucidated yet. Besides, ANS dysfunction has also been suggested to contribute to the heightened cardiovascular risk that accompanies these disorders^[@CR21],[@CR22]^. The psychotherapeutic interventions indicated for CHR-P individuals do not specifically address ANS dysfunction^[@CR23]^. Therefore, developing new therapies to improve ANS regulation in psychosis and CHR-P individuals might hold promise to prevent transition into full-blown psychosis and/or relapse and address potential cardiovascular comorbidities^[@CR2]^.

Heart rate (HR), the beat-to-beat fluctuation of instantaneous heart period over time and HR variability (HRV), provide inexpensive and non-invasive proximal measures of the ANS activity^[@CR24]^. Both the sympathetic and the parasympathetic branches of the ANS dually innervate the heart and modulate the heart rhythm^[@CR25]^. Sympathetic activity accelerates HR and decreases HRV, whereas parasympathetic activity has the opposite effect. Therefore, the inspection of HR and its resulting variability allows to draw inferences on the efferent activity of the ANS^[@CR24]^.

Previous studies have demonstrated increases in HR^[@CR26]--[@CR28]^ and decreases in HRV during rest in patients with schizophrenia compared with healthy control groups^[@CR20]^. Similar patterns have been found in first-degree relatives^[@CR29]--[@CR31]^ and in CHR-P individuals^[@CR32],[@CR33]^. The definitive mechanisms by which cardiac ANS regulation might be disrupted, leading to the increases in HR and decreases in HRV observed in emerging psychosis, are currently unknown. Consequently, we still lack targeted interventions to improve cardiac ANS regulation during emerging psychosis.

Oxytocin has been considered a promising compound for treating both positive and negative symptoms of psychosis^[@CR34]--[@CR36]^. Oxytocin participates in the modulation of several social and cognitive processes that are likely to contribute to the generation of both positive and negative symptoms (e.g., salience, reward processing and social approach). Intranasal oxytocin does not produce significant side effects, is highly tolerable and is not associated with adverse outcomes when delivered in the 18--40-IU doses typically used in single acute administration human studies^[@CR37]^ (including in children^[@CR38],[@CR39]^). Moreover, two small studies in patients with obsessive compulsive disorder have shown that daily doses of 160--320 IU do not increase the risk of side effects and are well tolerated^[@CR40],[@CR41]^. Therefore, in contrast to other drugs, intranasal oxytocin could hold therapeutic potential for improving positive and negative psychosis symptoms with minimal side effects. Evidence to favour specific preventive treatments over each other for improving positive or negative symptoms in CHR-P is currently limited^[@CR5],[@CR42],[@CR43]^. Some intranasal oxytocin studies have been recently conducted in patients with established psychosis (mostly schizophrenia)^[@CR44]^. However, the results have been mixed and mostly inconclusive.

In contrast with schizophrenia, the number of intranasal oxytocin studies conducted with people at CHR-P until now is surprisingly scarce. We have previously shown that a single acute dose of intranasal oxytocin (40 IU) modulates hippocampal perfusion (a key element of our current models of the neurobiological mechanisms underlying the onset of psychosis)^[@CR45]--[@CR47]^ and increases the levels of choline in the anterior cingulate cortex of men at CHR-P^[@CR48]^. However, while oxytocin has long been recognised for its roles in the regulation of the cardiovascular and ANSs^[@CR49]--[@CR51]^, we are still unclear about whether intranasal oxytocin might address the ANS dysfunction observed along the psychosis spectrum.

Oxytocin receptors are widely distributed throughout the central and peripheral ANS^[@CR52]^ and in the heart^[@CR53]^. Furthermore, pharmacological studies in rodents and humans have shown that oxytocin reduces blood pressure^[@CR54],[@CR55]^, decreases HR^[@CR56],[@CR57]^, modulates breathing^[@CR58]^ and increases HRV via parasympathetic activity^[@CR59],[@CR60]^. The evidence for the effects of oxytocin on HR and HRV in humans is mixed. Studies diverge between no impact of intranasal oxytocin on HR^[@CR60]--[@CR63]^ and decreased HR in pregnant women during oxytocin infusions^[@CR64]^. Studies on HRV have reported intranasal oxytocin-induced increases at rest in healthy subjects^[@CR59],[@CR60]^, patients with obstructive sleep apnoea^[@CR65]^, in pregnant women after oxytocin infusion^[@CR64]^, decreases during exposure to stress^[@CR66],[@CR67]^ or no effects at rest in both healthy individuals^[@CR63],[@CR66]^ and in men with Fragile X syndrome^[@CR68]^. We have failed to detect any significant effects of a single dose of intranasal (40 IU) or intravenous infusion (10 IU) of oxytocin on HR or HRV in healthy men over an extended period of observation post dosing (14--104 min)^[@CR63]^. Apart from the lack of consensus regarding the effects of oxytocin on HR/HRV in healthy humans^[@CR51]^, we also lack an in-depth understanding of the effects of oxytocin on ANS cardiac regulation in clinical populations where ANS dysregulation is present^[@CR69]^, such as in CHR-P.

The current proof-of-concept study comes to address this gap. We combined a single acute administration of intranasal oxytocin (40 IU) with plethysmography to investigate the effects of intranasal oxytocin on HR and HRV in CHR-P and healthy men. Focusing on people at CHR-P, who are typically antipsychotic naive^[@CR70],[@CR71]^, provides an invaluable opportunity to assess HR and HRV and investigate potential intranasal oxytocin effects in a population that have a high risk of developing psychosis (in particular the brief and limited intermittent psychosis subgroup^[@CR72]--[@CR74]^), without the confounding effects of antipsychotic medication. We hypothesised that, compared with healthy men, CHR-P men would show increased resting HR and decreased HRV (under placebo). We further hypothesised that intranasal oxytocin (compared with placebo) would decrease HR and increase HRV in CHR-P men to levels similar to those observed in healthy men.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

### CHR-P sample {#Sec4}

We recruited 30, help-seeking CHR-P men aged 18--35 from the OASIS^[@CR75]^ and Tower Hamlets Early Detection Services^[@CR3]^. One subject was removed due to protocol violation. We determined CHR-P status using the Comprehensive Assessment of At-Risk Mental States (CAARMS) 12/2006 criteria^[@CR76]^. For further details on our exclusion criteria, see ref. ^[@CR47]^. The study received National Research Ethics Service approval (14/LO/1692) and all subjects gave written informed consent.

### Healthy comparison sample {#Sec5}

We included data from a comparison group of 17 healthy males, aged 19--34, acquired in the context of another study. For further details on our inclusion and exclusion criteria, see ref. ^[@CR63]^. Participants gave written informed consent. King's College London Research Ethics Committee (PNM/13/14-163) approved the study.

Study design and procedures {#Sec6}
---------------------------

### CHR-P sample {#Sec7}

We used a randomised, double-blind, crossover single-dose challenge of intranasal oxytocin versus placebo design (1-week wash out). Participants self-administered 40 IU of intranasal oxytocin using a standard nasal spray. Our protocol followed the current practice in intranasal oxytocin pharmacological studies regarding the use of sprays to administer oxytocin^[@CR77]^. It included the self-administration of one puff (4 IU) of intranasal oxytocin (Syntocinon, 40 IU/ml, Novartis, Basel, Switzerland) or matched placebo (same excipients except oxytocin) every 30 s, alternating between nostrils, until 10 puffs were administered (40 IU), during a period of 5 min. Participants were randomly allocated to a treatment order (oxytocin/placebo or placebo/oxytocin). After drug administration, participants were guided to a magnetic resonance imaging (MRI) scanner (data already reported^[@CR47],[@CR78]^ or to be reported in forthcoming publications). During the MRI session, we acquired, in the following order, two arterial spin-labelling resting-state scans, two runs of BOLD fMRI during a theory-of-mind task^[@CR79]^, then two structural scans (T1 and FLAIR), a resting-state BOLD fMRI and a magnetic resonance spectroscopy scan at the end. Here we report pulse plethysmography and respiratory movement data that were collected during a resting-state BOLD--fMRI scan over a period of 8 min at 62.21 ± 3.46 min post dosing.

### Healthy comparison sample {#Sec8}

We include data from the two arms of a randomised, double-blind, crossover single-dose challenge study^[@CR63]^, where participants received 40 IU of intranasal oxytocin or placebo (same treatments and protocol as described for the CHR-P sample). After drug administration, participants were guided to an MRI scanner where we acquired a series of resting-state arterial spin labelling or BOLD--fMRI scans (data already reported^[@CR63]^ or to be reported in forthcoming publications). Here we report plethysmography/respiratory data acquired during a resting-state BOLD--fMRI scan over a period of 8 min matching the post-dosing temporal window as in the CHR-P group (57.01 ± 3.38 min post dosing).

In our previous in-depth characterisation of the pharmacodynamics of intranasal oxytocin in healthy men, we have demonstrated that 40 IU intranasal oxytocin induces sustained changes in brain's physiology and elevations in plasma oxytocin for an extended period of time post dosing^[@CR63],[@CR80]^, which includes the post-dosing interval during which we sampled HR/HRV in the current study. In both datasets, subjects were asked to abstain from using recreational drugs for at least 1 week and alcohol for at least 24 h prior to each session. Breath and urine screening were conducted before each session.

Physiological data acquisition and processing {#Sec9}
---------------------------------------------

Pulse plethysmography was continuously monitored during the resting BOLD--fMRI scan using MRI-compatible finger pulse oximetry while the participant rested in supine position, breathing spontaneously and fixating at a cross at the centre of a white screen. The data were recorded digitally as physiologic waveforms at a sampling rate of 50 Hz. Pulse plethysmography offers an easy and accurate approximation of inter-beat intervals (IBIs)^[@CR81]^. When sampling rates \> 25 Hz are used, time- and frequency-domain parameters of HR and HRV as assessed by pulse plethysmography are as reliable as those derived from the analysis of electrocardiogram data acquired with higher sampling rates^[@CR82]^. Heart beats were firstly automatically detected using an in-house script and then visually inspected and manually cleaned for misidentified beats. IBI values were then calculated. The resulting cleaned data were then transferred to *Kubios HRV analysis software* (MATLAB, version 2 beta, Kuopio, Finland). In addition to the manual cleaning of the data, the IBI time series were processed using automatic artefact detection and detrending (using smoothing priors, *λ* = 500), and cubic spline interpolation to replace automatically detected artefacts, as provided by *Kubios*. If more than 5% of the beats required correction, we decided to exclude these datasets^[@CR83]^. Then, we estimated HR and the high-frequency spectral power (0.15--0.40 Hz) of HRV (HF-HRV), using the standard *Kubios* pipeline. A detailed description of the analysis methods used to calculate these measures in *Kubios* has been provided in detail elsewhere^[@CR60],[@CR64]^. We focused on the high-frequency band because this component almost exclusively reflects parasympathetic modulation of the heart rhythm^[@CR24]^.

While we acquired 8 min of data in total, HR and HRV were calculated based on segments of 5 min free of artefacts (as required for pulse plethysmography to accurately reflect HRV when assessed by electrocardiography^[@CR84]^). Since the data were acquired in the context of a MRI scan, we excluded the first 2 min of acquisition to account for habituation to the imaging procedure and the last minute to avoid contamination from finger movement artefacts. This choice allowed us to maximise the amount of high-quality data included in the analysis.

A chest strain gauge was used to measure respiratory movements. Strain gauge signals were manually checked for artefacts and low-pass filtered with a fourth-order, Butterworth zero-phase filter of 0.20 Hz. Then we used a technique involving cross-correlation of the filtered respiratory signal with sinusoidal signals of different frequencies to estimate the time-varying frequency of the respiration (details described elsewhere^[@CR85]^).

Statistical analysis {#Sec10}
--------------------

All statistical analyses were conducted using SPSS-25 (<http://www-01.ibm.com/software/uk/analytics/spss/>) and JASP (version 0.8.5.1) for the Bayesian analyses (for some primers on Bayesian inference and how to implement it with JASP, see refs. ^[@CR86]--[@CR91]^). Data were first examined for normality of the distributions and for the presence of outliers. When variables were not normally distributed, we applied logarithmic transformation. To test our first hypothesis, we took HR and HF-HRV from the placebo sessions and compared the CHR-P and healthy men groups using an independent sample *t* test. Since our healthy men sample was smaller, and therefore a negative finding could simply reflect the lack of sensitivity, we followed up this analysis with a Bayesian independent sample *t* test to quantify relative evidence for both the null and alternative hypotheses. We then proceeded to test our second hypothesis where we examined condition, treatment and condition × treatment effects on HR and HF-HRV in two separate linear mixed models, with a random intercept for subject and treatment and condition as fixed effects. When a significant interaction was found, we followed up with post hoc tests for simple effects, applying *Sidak* correction for multiple comparisons.

### Post hoc analyses {#Sec11}

We conducted a series of post hoc analyses to investigate the potential confounding effect of respiratory frequency, body mass index (BMI), age or current medication in our findings. Furthermore, we also investigated whether HR or HR-HVR relates to clinical symptomatology in CHR-P men under placebo, or whether clinical symptomatology can predict intranasal oxytocin-induced increases on HF-HRV in CHR-P men. These analyses are fully described in [Supplementary Material](#MOESM1){ref-type="media"}.

In all of our analyses, we set statistical significance at *p* \< 0.05 (two-tailed). For all of our Bayesian analyses, we used Cauchy (Independent sample *t* test)/beta (correlations) priors' distributions centred around zero, with a width parameter of 1. However, we also performed robustness checks to assess sensitivity to the priors by assigning wide prior width (the plots illustrating these robustness checks can be found in Figs. [S1](#MOESM1){ref-type="media"}--[S3](#MOESM1){ref-type="media"}). An increase in Bayes factor (BF) in our analyses corresponds to an increase in evidence in favour of the null hypothesis. To interpret BF, we used the Lee and Wagenmakers' classification scheme^[@CR92]^: BF \< 1/10, strong evidence for alternative hypothesis; 1/10 \< BF \< 1/3, moderate evidence for alternative hypothesis; 1/3 \< BF \< 1, anecdotal evidence for alternative hypothesis; BF \> 1, anecdotal evidence for the null hypothesis; 3 \< BF \< 10, moderate evidence for the null hypothesis; BF \> 10, strong evidence for the null hypothesis.

Results {#Sec12}
=======

Sample characteristics {#Sec13}
----------------------

For a brief summary of the sociodemographics of the two samples see Table [1](#Tab1){ref-type="table"}. The two groups did not differ in age, height, weight or BMI (all *p* \> 0.347). Regarding CHR-P subgroup composition (using CAARMS)^[@CR93]^, our final sample included 6 men with brief limited intermittent psychotic symptoms, 22 with attenuated positive symptoms (APS) and 1 with genetic risk and deterioration. In the CHR-P group, eight men were under current pharmacological treatment (three on sertraline, one on fluoxetine, one on amitriptyline, one on mirtazapine and diazepam and one on an unknown antidepressant class). These treatments are typically employed in this group, given their high load of comorbid affective disorders^[@CR94]^. Transition to psychosis was identified for 4 men within a follow-up of 26 months, but the follow-up is still ongoing. The mean CAARMS-APSs score for the CHR-P group was 11.86 (±3.35 standard deviation). Participants in either cohort could not discriminate if they had received intranasal oxytocin or placebo.Table 1Sociodemographic information (summary descriptive statistics).DescriptiveVariableGroupMeanStandard deviation*N* (valid)AgeCHR-P22.934.7729HC24.245.3317HeightCHR-P178.598.6127HC178.155.5917WeightCHR-P72.3510.6228HC74.508.9417BMICHR-P22.683.0027HC23.411.9717In this table, we provide a statistical summary of some sociodemographic characteristics collected in both datasets. *CHR-P* clinical high-risk for psychosis, *HC* healthy men.

### Condition, treatment, and condition × treatment effects on respiratory frequency {#Sec14}

We did not find any significant effect of condition (*F*(1,61.84) = 3.53, *p* = 0.07), treatment (*F*(1,61.84) = 6.00 × 10^−3^, *p* = 0.94) or condition × treatment (*F*(1,61.84) = 0.05, *p* = 0.83) on respiratory frequency. In Table [S1](#MOESM1){ref-type="media"}, we present the exploratory correlations between RF, HR and HF-HRV. Notably, we found a significant negative correlation between RF and HF-HRV only for CHR-P men in the oxytocin session.

CHR-P and healthy men did not differ in HR or HF-HRV under placebo {#Sec15}
------------------------------------------------------------------

We did not find any significant differences between healthy and CHR-P men for baseline HR (*T*(40) = −0.65, *p* = 0.52, BF = 3.47) and HF-HRV (*T*(40) = 0.68, *p* = 0.50, BF = 3.42) (Table [2](#Tab2){ref-type="table"}).Table 2Heart rate (HR), high-frequency heart-rate variability (HF-HRV) and respiratory frequency (RF) summary descriptive statistics.DescriptiveMETRICGroupTreatmentMeanStandard deviation*N* (valid)HRCHR-POT61.799.1628CHR-PPL61.328.1528HCOT58.818.1916HCPL59.716.0214HF-HRVCHR-POT7.511.0828CHR-PPL7.161.0028HCOT7.190.9616HCPL7.370.8014RFCHR-POT16.482.2827CHR-PPL16.322.8326HCOT15.361.8516HCPL15.442.3514*CHR-P* clinical high-risk for psychosis, *HC* healthy men, *OT* oxytocin, *PL* placebo.

Intranasal oxytocin (compared with placebo) increased HF-HRV in CHR-P but not in healthy men {#Sec16}
--------------------------------------------------------------------------------------------

### Heart rate {#Sec17}

We did not observe treatment (*F*(1,40.45) = 0.07, *p* = 0.79), condition (*F*(1,44.03) = 0.51, *p* = 0.48) or treatment × condition (*F*(1,40.45) = 0.33, *p* = 0.57) effects on HR (Fig. [1a](#Fig1){ref-type="fig"}).Fig. 1Condition, treatment, and condition × treatment effects on heart rate (a) and high-frequency heart-rate variability (b).Heart rate (HR) (**a**) and high-frequency heart-rate variability (HF-HRV) (**b**) descriptive for each treatment level within each group. Violin plots represent the smoothed distribution of the data. Box plots represent the distribution of the HR/HF-HRV values for each treatment level in each condition (median is indicated by the black central line; upper and lower whiskers denote the highest and the lowest datum within 1.5 interquartile range of the upper and lower quartiles). We tested for the main effects of condition, treatment, and the condition × treatment interaction on HR and HF-HRV using two separate linear mixed models. Statistical significance was set to \**p* \< 0.05. Abbreviations: HC healthy controls, CHR-P clinical high-risk for psychosis, OT intranasal oxytocin, PL placebo.

### High-frequency HR variability {#Sec18}

We found a significant treatment × condition interaction on HF-HRV (*F*(1,39.93) = 7.17, *p* = 0.01). The interaction was driven by an increase in HF-HRV after intranasal oxytocin (compared with placebo) in CHR-P men (*F*(1,38.81) = 14.11, *p* = 1.00 × 10^−3^) but not in healthy men (*F*(1,40.45) = 0.40, *p* = 0.53). There were no significant differences in HF-HRV between CHR-P and healthy men under oxytocin or placebo (all *p* \> 0.34). There were no significant main effects of condition (*F*(1,44.53) = 0.06, *p* = 0.81) or treatment (*F*(1,39.93) = 2.71, *p* = 0.11) on HF-HRV (Fig. [1b](#Fig1){ref-type="fig"}).

Post hoc analyses {#Sec19}
-----------------

### Age, BMI, respiratory frequency and current medication {#Sec20}

Accounting for age, BMI, respiratory frequency and current medication did not affect our reported results.

### Association between HR/HF-HRV under placebo and clinical symptomatology in CHR-P men {#Sec21}

We did not find any significant correlation between HR (*r* = 0.08, *p* = 0.71, BF = 4.11) (Fig. [2a](#Fig2){ref-type="fig"}) or HF-HRV (*r* = −0.04, *p* = 0.89, BF = 3.59) (Fig. [2b](#Fig2){ref-type="fig"}) under placebo and CAARMS scores.Fig. 2Association between heart rate (a), high-frequency heart-rate variability (b), and attenuated positive symptoms in men at clinical high risk for psychosis.Scatter plots showing the absence of correlation between heart rate (**a**) or high-frequency heart-rate variability (**b**) in the placebo session and attenuated positive symptoms (as assessed by the Comprehensive Assessment of At-risk Mental States (CAARMS)) in men at clinical high risk for psychosis. The blue line represents the fitting of a linear regression and the shadow the respective 95% confidence interval. The histograms on the top of each axis show the density distribution of each variable.

### Association between clinical symptomatology and intranasal oxytocin-induced changes in HF-HRV in CHR-P men {#Sec22}

Baseline CAARMS scores did not predict intranasal oxytocin-induced changes in HF-HRV in CHR-P men (*r* = 0.11, *p* = 0.58, BF = 3.56) (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Association between high-frequency heart-rate variability response to intranasal oxytocin and attenuated positive symptoms in clinical high risk for psychosis men.Scatterplot showing the absence of correlation between the response of the high-frequency heart-rate variability (HF-HRV) to intranasal oxytocin and attenuated positive symptoms (as assessed by the Comprehensive Assessment of At-risk Mental States (CAARMS)) in men at clinical high risk for psychosis. ΔHF-HRV corresponds to the difference between the HF-HRV values of the oxytocin and placebo sessions (oxytocin--placebo). The blue line represents the fitting of a linear regression and the shadow the respective 95% confidence interval. The histograms on the top of each axis show the density distribution of each variable.

Discussion {#Sec23}
==========

In this study, we show that a single dose of intranasal oxytocin (compared with placebo) increases HR variability in CHR-P but not in healthy men. Nevertheless, we failed to replicate previous evidence suggesting that CHR-P, compared with healthy men, shows increased resting HR and decreased HRV. Our proof-of-concept findings support the idea that intranasal oxytocin may be of potential clinical value in improving autonomic regulation, by enhancing parasympathetic activity, during CHR-P. Given the lack of evidence for specific preventive treatments in this population, similar proof-of-concept studies that demonstrate disease-engagement targets are essential to inform future drug discovery efforts.

Do men at clinical high risk for psychosis present alterations in HR and HRV at rest? {#Sec24}
-------------------------------------------------------------------------------------

We did not find any significant group differences in HR or HRV between CHR-P and healthy men. The absence of significant group differences on HR and HRV was also supported by our Bayesian analysis, which showed that our null hypothesis of no differences between CHR-P and healthy men is about three times more likely than the alternative hypothesis of significant group differences (moderate evidence in favour of the null hypothesis). Our findings remained unchanged when we accounted for age, BMI, respiratory frequency or current medication status. Altogether, our findings challenge the notion that cardiac autonomic regulation is already impaired during the high-risk stages that precede the onset of full-blown psychosis, and would argue that autonomic alterations are linked to diagnosable clinical psychosis rather than constituting a general vulnerability characteristic. Consistent with this idea, in our exploratory analyses, we also did not find a correlation between psychopathology (CAARMS scores for APSs) and HR or HRV in CHR-P men.

In contrast to studies on established psychosis^[@CR32],[@CR33]^, the number of studies investigating HR and HRV in CHR-P samples has been sparse. We are aware of only four studies. One study reported increased HR and decreased HRV during CHR-P and established psychosis, when compared with healthy controls and siblings, both at rest and during exposure to social stressors. The CHR-P and established psychosis groups did not differ in HR or HRV^[@CR95]^. Another study found increased baseline-resting HR in CHR-P compared with low-risk controls, but did not find any difference in HRV^[@CR33]^. Yet, two further studies reported no differences on HR or HRV between CHR-P and healthy controls, relatives or psychiatric controls matched for depression/anxiety, even though they reported increased HR and decreased HRV for clinically psychotic patients, compared with healthy controls^[@CR96],[@CR97]^.

There are certain differences among the studies looking at HR/HRV in CHR-P (including our own study) that may help explain the inconsistent findings among them. First, there are gender differences in resting HRV (women, compared with men, present lower resting HRV^[@CR98],[@CR99]^). The inclusion of samples of varied gender composition (ours focused on men) makes direct comparisons between studies challenging, especially if there is a gender-by-treatment interaction regarding the effects of HR/HRV. Second, in the two studies^[@CR33],[@CR95]^ where differences were evident at rest, participants had been exposed to social stressor paradigms that might have elicited anticipatory stress responses during the "resting" HR/HRV measurements. These anticipatory responses may have amplified the differences between the CHR-P/established psychosis and the healthy controls/siblings' groups. In our study, the plethysmography data were acquired at rest---but participants were in the MRI environment, which could have been perceived as distressing^[@CR100]^. To account for habituation to the imaging procedure, we excluded the first 2 min of recording. Therefore, we believe that our experimental setup resembles better the one used in the latter two studies^[@CR96],[@CR97]^ that also reported no resting HR/HRV differences between CHR-P and healthy individuals/relatives. Third, in our study, there was a difference in the procedure for data acquisition between the CHR-P and healthy groups that should be considered. In the healthy group, participants had been cannulated for repeated blood sampling, and a small blood sample (5 ml) had been drawn preceding the resting BOLD--fMRI scan. This procedure was not present in our CHR-P protocol. It is possible that this procedure added discomfort/perceived distress or compensatory autonomic responses to healthy participants that could have attenuated existent HR/HRV differences from CHR-P men. Finally, in our study, we measured HR/HRV, in both groups, after a long scanning period during which participants laid in supine position. In studies where HR/HRV have been reported to differ between CHR-P and healthy controls, recordings were done in the sitting/orthostatic position^[@CR33],[@CR95]^. Body position has been shown to affect cardiac autonomic regulation^[@CR101]^. Therefore, we cannot also exclude the contribution of this factor in mitigating potential existent differences between groups on HR/HRV, if they existed.

Can intranasal oxytocin increase resting HRV in CHR-P men? {#Sec25}
----------------------------------------------------------

We did not detect a treatment or treatment × condition effect on HR. However, we found a significant treatment × condition effect on HF-HRV, reflecting an increase in HF-HRV after intranasal oxytocin (compared with placebo) in CHR-P but not in healthy men. Importantly, our findings remained unaltered after accounting for age, BMI, current medication or respiratory frequency. Intranasal oxytocin-induced increases in HF-HRV were not predicted by the severity of APSs. Altogether, our findings suggest that intranasal oxytocin (40 IU), compared with placebo, increases cardio-parasympathetic activity in CHR-P men, irrespective of the severity of the APSs.

The absence of the effects of intranasal oxytocin on HR in the current study is not fully surprising. Apart from one study, which was conducted in pregnant women during continuous infusion of oxytocin, that reported bradycardic effects^[@CR102]^, four other studies (including one of our research group using the same healthy cohort^[@CR63]^) have shown that intranasal oxytocin (40 IU) (compared with placebo) does not affect HR in humans^[@CR60]--[@CR62]^. In animal models, the evidence for the effects of oxytocin on HR diverges between decreases^[@CR103]^, increases^[@CR58]^ and no effects^[@CR104]^. A lack of change in HR after oxytocin administration has been interpreted in the context of putative stimulatory effects on both branches of the ANS, which may cancel each other out^[@CR62],[@CR104]^. Since we did not assess cardiac sympathetic regulation in our sample, we cannot say whether the same applies to our findings. Furthermore, we also should acknowledge that it is difficult to interpret HR data (in our study and in others) without considering blood pressure, as changes in HR may be compensatory^[@CR105]^. This aspect should be taken into consideration in future studies revisiting this question.

The evidence for the effects of oxytocin on HRV in humans has been mixed. Studies on HRV have reported intranasal oxytocin-induced increases at rest in healthy subjects^[@CR59],[@CR60]^ and patients with obstructive sleep apnoea^[@CR65]^, and in pregnant women after oxytocin infusion^[@CR64]^, decreases during exposure to stress^[@CR66],[@CR67]^ or no effects at rest in both healthy individuals^[@CR63],[@CR66]^ and in men with Fragile X syndrome^[@CR68]^. Our own work has failed to detect any significant effects of a single dose of intranasal (40 IU) or intravenous (10 IU) oxytocin on resting HRV in healthy men over an extended period of observation post dosing^[@CR63]^.

There are some plausible hypotheses that might explain apparent discrepancies in the literature regarding the effects of intranasal oxytocin on HR or HRV in healthy participants, or differences between clinical and healthy groups in the oxytocin treatment response. We discuss three of these hypotheses, noting that some predictions may be contradictory and hence require further research. First, following current models of the pharmacodynamics of intranasal oxytocin in humans, which have suggested an inverted U-shape curve of response^[@CR106],[@CR107]^, it is tempting to speculate that our dose (40 IU) may have been higher than the optimal dose to achieve increases in HRV in healthy men. Indeed, the two studies reporting significant increases after intranasal oxytocin in healthy men used doses of 20--24 IU. We need studies to examine the dose--response effects of intranasal oxytocin on HRV in humans. Second, the oxytocin signalling pathway may be more sensitive to exogenous oxytocin in CHR-P men. This hypothesis is consistent with evidence from two studies. The first study reported increased oxytocin and oxytocin receptor mRNA expression in peripheral blood lymphocytes in first-episode schizophrenia patients when compared with healthy controls^[@CR108]^. The second study reported decreased methylation of the oxytocin receptor gene promoter, which would typically result in increased oxytocin receptor expression, in peripheral blood lymphocytes of women with a recent schizophrenia onset or at CHR-P, when compared with healthy women^[@CR109]^. In contrast, there is also evidence of region-specific decreases in oxytocin receptor expression (in the temporal cortex/cerebellum) in the brain of patients with established psychosis, compared with healthy controls^[@CR110]^. To the extent that such alterations are present in CHR-P in systems involved in the regulation of HR/HRV, this might predict an attenuated HR/HRV response to exogenous oxytocin and hence, if an inverted U-shape dose--response model is true, implying that an increased dose (compared with healthy men) is required in CHR-P men to achieve an optimal effect. While plausible, these hypotheses remain speculatory at the moment and therefore require further research.

Currently, it is unclear if the effects of oxytocin on HRV should be attributed to direct actions on peripheral elements of the ANS and cardiovascular systems, whether they are mediated via actions on central targets that regulate peripheral ANS activity, such as the amygdala (a brain area often implicated in the effects of intranasal oxytocin^[@CR111]^), or both. Future studies combining the concomitant administration of oxytocin and a non-brain receptor antagonist with neuroimaging and physiological recordings may help us to disambiguate this question.

Limitations {#Sec26}
-----------

First, we note that while our primary hypotheses were a priori (i.e., they were specified before conducting any analyses, and we are explicit about the instances when they are not), they were not part of the initial study protocols. Therefore, power calculations for these specific analyses had not been conducted a priori. Recognising the importance that the issue of statistical might have for the appraisal of our findings, we conducted some post hoc power analyses to investigate what is the lowest effect size our samples would have allowed us to detect with an acceptable statistical power of 80% in two-tailed tests for each of our main hypothesis (which we present in Fig. [S4](#MOESM1){ref-type="media"}). For our first hypothesis (differences in HR and HRV between healthy and men at CHR-P under placebo), we estimated that our samples (HC: *n* = 14 valid cases; CHR-P: *n* = 28 valid cases) would have allowed us to detect, using an independent sample *t* test, a large effect size of *d* = 0.94 (Fig. [S4A](#MOESM1){ref-type="media"}). Given that differences between healthy and CHR-P individuals on HR or HRV have been previously reported within the *d* = 0.20--0.50 range^[@CR112]^, our study was underpowered to test our first hypothesis. We used Bayesian statistics to quantify the relative evidence favouring the null and alternative hypotheses to explore this question further. We found that our data support the null hypothesis of no differences between CHR-P and healthy men on HR/HRV under placebo (even though the evidence in favour of the null hypothesis was only moderate). For our second hypothesis (effects of intranasal oxytocin on HR and HRV in men at CHR-P), our sample size (intranasal oxytocin: *n* = 28 valid cases; placebo: *n* = 28 valid cases) would have allowed us to detect, using a two-sided paired *t* test, a medium effect size of *d* = 0.55 (Fig. [S4B](#MOESM1){ref-type="media"}). Given that a previous study has reported effect sizes for intranasal oxytocin-induced increases in HRV within the *d* = 0.20--0.50 range^[@CR113]^, our sample size for testing the second hypothesis was reasonable. Given the power constraints of this study, our findings should be considered preliminary and we encourage replication studies.

Second, we only included men, which limits our ability to extrapolate our findings to women---especially when the effects of intranasal oxytocin may vary across genders^[@CR114]^. Third, our findings are limited to the dose (40 IU), regime of administration (single) and time post dosing we employed. Future studies should investigate a wider range of doses, different regimes of administration (single vs. chronic) and time course of these effects. Fourth, while we could exclude the potential confounding effect of respiratory frequency on our findings, we could not perform an in-depth investigation of the respiratory dynamics, including respiratory depth^[@CR115]^. Therefore, we cannot exclude the potential contribution of this confound. Fifth, our physiological data were acquired during an MRI scan. It is possible that the distress associated with the MRI environment might have affected our findings somehow (e.g., by attenuating differences between CHR-P and healthy men or exacerbating the effects of intranasal oxytocin in men at CHR-P, who might perceive the MRI environment as particularly distressing). Future studies should attempt to replicate our findings outside of the MRI environment. Finally, in the CHR-P group, participants had performed a theory-of-mind task^[@CR79]^, followed by two structural scans, before the beginning of the resting-state BOLD--fMRI data. Our protocol for the healthy sample only included resting-state scans. While the inclusion of the two structural scans (total duration \~7 min) between the task and the resting-state BOLD--fMRI scan is likely to have minimised any potential transference effects, we cannot exclude a potential contribution of task × intranasal oxytocin interaction to the significant increases in HRV we report herein for CHR-P men.

Conclusion {#Sec27}
==========

In this proof-of-concept study, we show that intranasal oxytocin (40 IU) increases cardio-parasympathetic activity in CHR-P but not in healthy men, demonstrating a potential disease-engagement psychopharmacological target. Our findings support the need to investigate further intranasal oxytocin as an intervention to improve ANS regulation during the high-risk stage of psychosis. Heightened ANS response to psychosocial stressors has been suggested to contribute to psychosis and accompanying increased cardiovascular risk. Hence, it is conceivable that, by increasing cardio-parasympathetic activity, intranasal oxytocin might hold promise to prevent transition into full-blown psychosis and/or relapse and address potential cardiovascular comorbidities^[@CR2]^ in patients with psychosis or at risk. This hypothesis should be addressed in further longitudinal clinical studies investigating the effects of chronic administrations of oxytocin. Furthermore, given that oxytocin might also improve other deficits of CHR-P, such as social functioning, it is tempting to speculate that intranasal oxytocin could constitute an innovative treatment, with multiple potential therapeutic benefits cutting across different symptom domains, and minimal side effects for people at CHR-P. In the absence of specific preventive treatments in this population, similar proof-of-concept studies are essential to inform and guide potential future therapeutic advances.
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